Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.60 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.60 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23031873 | 1.00 | MAPK1 (0.74) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL26249989 | 1.00 | MAPK1 (0.74) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL25767297 | 1.00 | MAPK1 (0.74) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL22021801 | 1.00 | MAPK1 (0.74) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL19871891 | 1.00 | MAPK1 (0.74) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL16392632 | 0.89 | MAPK1 (0.73) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL16393106 | 0.89 | MAPK1 (0.73) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL2482719 | 0.89 | MAPK1 (0.73) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL24496201 | 0.89 | MAPK1 (0.63) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL10333760 | 0.88 | MAPK1 (0.75) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023041079-A9 | LPA INHIBITOR AND USE THEREOF | 上海金中锘美生物医药科技有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-10745700-B2 | Nucleic acid conjugate | KYOWA KIRIN CO., LTD. (JP) | 2020-08-18 | — | — | US | disclosed |
| EP-3546579-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190055558-A1 | NUCLEIC ACID CONJUGATE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | NOVO NORDISK A/S (DK) | 2017-10-26 | — | — | US | disclosed |
| EP-2929031-B1 | PCSK9 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745700-B2 | Nucleic acid conjugate | SLC29A1, NSUN2, H1-2 | MAPK1 1162/4885LGALS8 750/4885LGALS3 556/4885 |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | ADAR, NCL, SSU72 | MAPK1 4492/4885LGALS8 702/4885LGALS3 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.